First long-acting protection from HIV for women to launch in 2022
The dapivirine ring will be the first long-acting option that women can use to reduce their risk of HIV transmissionm representing an important milestone in prevention technologies.
The world’s first long-acting option to protect women from HIV will hit the market next year, following its development in Belfast.
For the past 20 years, researchers from the School of Pharmacy at Queen’s University Belfast have been supporting the development of a new drug-releasing vaginal ring to protect women from infection with the human immunodeficiency virus (HIV).
